Metformin, widely used to treat type 2 diabetes, may help alleviate the side effects of hormone therapy for prostate cancer. This conclusion was reached by researchers from the University of Miami, who published their findings in the journal EMBO Molecular Medicine.

The scientists found that the drug increases levels of the molecule Lac-Phe—a compound typically produced in the body after intense physical exercise and involved in regulating energy metabolism, appetite, and body weight. Notably, this effect was observed even in patients who do not engage in physical activity.

This is particularly important for men undergoing hormone therapy, which is often accompanied by pronounced fatigue, weight gain, and metabolic disturbances, making it difficult to maintain physical activity. Metformin can partially mimic the metabolic effects of exercise, helping to maintain energy balance and reduce the negative consequences of treatment.

The authors emphasize that the drug does not replace physical exercise and does not directly affect the tumor. However, it may improve treatment tolerance and patients’ quality of life. In the future, researchers plan to further investigate the role of Lac-Phe and the potential of metformin as an adjunct therapy in oncology.